āK
t
GSK plc filed its 2025 Annual Report on Form 20-F with the Securities and Exchange Commission on March 6, 2026, including audited financial statements for the year ended December 31, 2025. The report is available online, and hard copy versions will be available on or about March 25, 2026. Shareholders can request a free hard copy of the complete audited financial statements for the year ended December 31, 2025.
| Date | 6 Mar 2026 |
| Time | 14:21:19 |
| Category | Miscellaneous |
| ID | 7305V |
Issued: 6 March 2026, London UK
GSK plc 2025 Annual Report on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 6 March 2026 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2025. GSK's 2025 Annual Report on Form 20-F is available online at GSK's website at: https://annualreport.gsk.com and also online at www.sec.gov.
A hard copy version of the GSK 2025 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2026.
Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2025, free of charge, by either:
|
(i) |
writing to Computershare Investor Services, our registrars in the UK, at the following address: Computershare Investor Services, The Pavilions, Bridgwater Road, Bristol BS99 6ZY, United Kingdom, or by telephone on +44 (0) 370 707 1595 (please use the country code if calling from outside the UK); or
|
|
(ii) |
writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: Computershare Trust Company N.A., PO Box 43304, Providence, RI 02940-3304, or by telephone on +1 877 353 1154 or +1 781 575 4992 (outside the US).
|
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Victoria Whyte
Company Secretary
6 March 2026
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2025.
ā
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG